Wednesday - January 8, 2025

LOGIN  |  REGISTER
Viking Therapeutics

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

September 11, 2024 | Last Trade: US$1.89 0.03 -1.56

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. ET in New York, NY.

David R. Parkinson, President and Chief Executive Officer, Peter Virsik, Chief Operating Officer and Executive Vice President, and David S. Wood, Chief Financial Officer, will participate in a fireside chat.

A live webcast of the fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essaphrma.com, and follow us on X and LinkedIn.

Contacts  
ESSA Pharma Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
pvirsik@essapharma.com

Investors and Media:
Argot Partners
212.600.1902
essa@argotpartners.com 

Assertio

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page